These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7846423)

  • 1. On the development of the Medical Research Council trial of alpha-interferon in metastatic renal carcinoma. Urological Working Party Renal Carcinoma Subgroup.
    Fayers PM; Cook PA; Machin D; Donaldson N; Whitehead J; Ritchie A; Oliver RT; Yuen P
    Stat Med; 1994 Nov; 13(21):2249-60. PubMed ID: 7846423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
    Lancet; 1999 Jan; 353(9146):14-7. PubMed ID: 10023944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is treatment with interferon-alpha effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions.
    Royston P; Sauerbrei W; Ritchie A
    Br J Cancer; 2004 Feb; 90(4):794-9. PubMed ID: 14970855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma.
    Kriegmair M; Oberneder R; Hofstetter A
    Urology; 1995 May; 45(5):758-62. PubMed ID: 7747370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modest effect of interferon alfa on metastatic renal-cell carcinoma.
    Amato R
    Lancet; 1999 Jan; 353(9146):6-7. PubMed ID: 10023941
    [No Abstract]   [Full Text] [Related]  

  • 6. Interferon-alpha and survival in renal cell cancer.
    Fossa S; Jones M; Johnson P; Joffe J; Holdener E; Elson P; Ritchie A; Selby P
    Br J Urol; 1995 Sep; 76(3):286-90. PubMed ID: 7551834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial.
    Steineck G; Strander H; Carbin BE; Borgström E; Wallin L; Achtnich U; Arvidsson A; Söderlund V; Näslund I; Esposti PL
    Acta Oncol; 1990; 29(2):155-62. PubMed ID: 2185803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
    Pantuck AJ; Belldegrun AS; Figlin RA
    N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
    [No Abstract]   [Full Text] [Related]  

  • 10. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial.
    Mickisch GH; Garin A; van Poppel H; de Prijck L; Sylvester R;
    Lancet; 2001 Sep; 358(9286):966-70. PubMed ID: 11583750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
    Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
    Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890).
    Dutcher JP; Fine JP; Krigel RL; Murphy BA; Schaefer PL; Ernstoff MS; Loehrer PJ
    Med Oncol; 2003; 20(3):271-81. PubMed ID: 14514977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma.
    Naglieri E; Lopez M; Lelli G; Morelli F; Amodio A; Di Tonno P; Gebbia N; Di Seri M; Chetri MC; Rizzo P; Abbate I; Casamassima A; Selvaggi FP; Colucci G
    Anticancer Res; 2002; 22(5):3045-51. PubMed ID: 12530040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MRC randomised-controlled trial of interferon-alpha, interleukin-2 and 5-fluorouracil vs interferon-alpha alone in patients with advanced renal cell carcinoma (RE04): rationale and progress.
    Larkin JM; Gore ME
    Clin Oncol (R Coll Radiol); 2005 Aug; 17(5):319-21. PubMed ID: 16097560
    [No Abstract]   [Full Text] [Related]  

  • 15. Nephrectomy for metastatic renal-cell cancer.
    Copur MS; Ledakis P; Norvell M
    N Engl J Med; 2002 Apr; 346(14):1095-6. PubMed ID: 11936126
    [No Abstract]   [Full Text] [Related]  

  • 16. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
    Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
    Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors and the role of nephrectomy in metastatic renal cell carcinoma.
    Uygur MC; Usubütün A; Ozen H; Ayhan A; Kendi S
    J Exp Clin Cancer Res; 1999 Sep; 18(3):397-401. PubMed ID: 10606187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytokine therapy of metastatic renal cell carcinoma].
    Otto T; Goepel M; Luboldt HJ; Rübben H
    Urologe A; 1995 May; 34(3):200-3. PubMed ID: 7610512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
    Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
    Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.